Clinical trials · California
Breast Cancer Invasive clinical trials in California
We’re tracking 71 recruiting breast cancer invasive studies with a site in California — including Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07505797Recruiting
Ultrasound imaging study for suspicious breast lesions
This study is testing a new ultrasound device (ATUSA) to see how well it can image breast lesions that have been classified as suspicious (BI-RADS 4 or 5). If you have a recent finding that needs further evaluation, this research might help improve detection methods.
Sacramento, CaliforniaAges 18–94 - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Auburn, CaliforniaAges 18 years+ - NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Long Beach, CaliforniaAges 18 years+ - NCT07054190RecruitingPhase 2
Testing inavolisib for early-stage PIK3CA-mutated breast cancer
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT07007559RecruitingPhase 2
Evorpacept with trastuzumab and chemo for HER2-positive breast cancer
This study tests an experimental drug called evorpacept when given with trastuzumab and chemotherapy for people with HER2-positive breast cancer that has spread. The goal is to see if this combination can shrink tumors or slow down the cancer.
Orange, CaliforniaAges 18 years+ - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Los Angeles, CaliforniaAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Arroyo Grande, CaliforniaAges 18 years+ - NCT06860815RecruitingPhase 2
Cemiplimab with liver radiation for breast cancer that spread to the liver
This trial tests a combination of a drug called cemiplimab (an immunotherapy that helps your immune system fight cancer) and a type of targeted radiation (Y-90 SIR-Spheres) given directly to liver tumors. It is for people with breast cancer that has spread to the liver and who have already had at least one type of chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT06763328RecruitingPhase 3
Metformin for insulin resistance after breast cancer chemo
This study tests if metformin, a common diabetes medicine, can help reduce insulin resistance in women who finished chemotherapy for early-stage breast cancer. It aims to improve long-term health and prevent future problems.
Riverside, CaliforniaAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06445738Recruiting
Can some women safely skip radiation after breast cancer surgery?
This trial is for women 50 and older with early-stage, hormone-positive or HER2-positive breast cancer. It tests whether it is safe to skip radiation therapy after a lumpectomy if an MRI before surgery shows the breast tissue looks a certain way.
San Francisco, CaliforniaAges 50 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT06268665RecruitingPhase 2
Tart Cherry Juice for Preventing Nerve Damage from Chemotherapy
This study tests whether tart cherry juice can help prevent nerve damage (peripheral neuropathy) caused by the chemotherapy drug paclitaxel. Participants drink tart cherry juice daily during their 12 weeks of paclitaxel treatment.
Sacramento, CaliforniaAges 18 years+ - NCT06113016RecruitingPhase 2
Preventing frailty with fisetin and exercise in breast cancer survivors
This study tests whether adding a supplement called fisetin to an exercise program can help prevent frailty in women who have finished chemotherapy for early-stage breast cancer. If you are postmenopausal, have completed chemo within the last year, and can walk a certain distance, you may qualify.
Alhambra, CaliforniaAges Any age - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06092892RecruitingPhase 2
Upfront targeted lymph node removal for early breast cancer
This trial is for women age 45 and older with early ER-positive breast cancer that has spread to the lymph nodes under the arm. It tests a surgery approach where the main tumor and only a few key lymph nodes (rather than many) are removed.
Los Angeles, CaliforniaAges 45 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Walnut Creek, CaliforniaAges 18 years+ - NCT04553770RecruitingPhase 2
Trastuzumab deruxtecan with or without anastrozole for early breast cancer
This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.
Fullerton, CaliforniaAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT05964504Recruiting
Registry study for metastatic lobular breast cancer
This study collects health information from adults with invasive lobular breast cancer that has spread (metastatic) to help researchers understand factors linked to survival. Joining may help build better knowledge for future treatments and care planning.
San Diego, CaliforniaAges 18 years+ - NCT05941520RecruitingPhase 2
Acolbifene vs low-dose tamoxifen to prevent breast cancer
This Phase 2 trial compares acolbifene and low-dose tamoxifen to see which better lowers breast cancer risk in premenopausal women at high risk. You would be followed with health visits, blood tests, and a breast tissue sampling procedure.
Duarte, CaliforniaAges 35 years+ - NCT05902507Recruiting
MRI guidance during breast cancer radiation treatment
This trial studies using MRI images to help plan and guide radiation therapy after breast-conserving surgery. It may help doctors target the right area more accurately while keeping treatment standard and safe.
San Francisco, CaliforniaAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Cameron Park, CaliforniaAges 18 years+
Where these studies are running in California
Institutions with a site for the recruiting breast cancer invasive studies listed above.
- City of Hope · 7 studies
- Cedars-Sinai Cancer - Tarzana · 4 studies
- Huntington Memorial Hospital · 4 studies
- Tower Cancer Research Foundation · 4 studies
- University of California, Davis · 4 studies
- Alta Bates Summit Medical Center-Herrick Campus · 3 studies
- Cedars-Sinai Medical Center · 3 studies
- Loma Linda University Medical Center · 3 studies
What taking part in a breast cancer invasive study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Breast Cancer Invasive trials in other states
Common questions
- Are there breast cancer invasive clinical trials in California?
- Yes. We're currently tracking 71 recruiting breast cancer invasive studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast cancer invasive study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast cancer invasive trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast cancer invasive studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.